Sinopharm Group's (HKG:1099) subsidiary China National Accord Medicines (SHE:000028, SHE:200028) expects to log a net profit attributable to shareholders between 561 million yuan and 760 million yuan for 2024.
The expected net profit is 52.48% to 64.92% lower than 1.60 billion yuan recorded for 2023, a Sunday Hong Kong bourse filing said.
China National Accord Medicines also expects to see basic earnings between 1.01 yuan per share and 1.37 yuan per share for the reporting period, compared with 2.87 yuan per share recorded for the prior year.
The decrease in expected attributable net profit was attributed to impairment of intangible assets arising from goodwill and other assets including receivables and inventories, and allocation of certain acquisition consideration.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。